Abstract
Neoadjuvant chemotherapy (NAC) followed by interval debulking does not present inferior results to those of primary cytoreduction and offers the opportunity to evaluate chemo-sensitivity in vivo. Chemotherapy response score (CRS) have been shown to correlate with outcome with a complete or near-complete (CRS3) response predicting improved progression-free survival (PFS). Our proposal is to determine the prevalence of BRCA1/2 mutations and to search for other molecular mechanisms of HR inactivation which could explain the great sensitivity to platinum salts.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
